Literature DB >> 3000160

Systemic hypertension after cardiac transplantation: effect of cyclosporine on the renin-angiotensin-aldosterone system.

M Bellet, C Cabrol, P Sassano, P Léger, P Corvol, J Ménard.   

Abstract

Fifteen patients who had undergone cardiac transplantation and who had hypertension (164 +/- 14/112 +/- 13 mm Hg), aged 16 to 57 years (mean 39), were treated with cyclosporine, 8 +/- 3 mg/kg/day, and prednisolone, 0.27 +/- 0.1 mg/kg/day, for 63 to 788 days (mean 288) after transplantation. They were not given antihypertensive drugs. Before treatment, the mean urinary sodium level was 104 +/- 48 mEq/day. Two discrete abnormalities accompanied their high blood pressure (BP): an increase in serum creatinine levels (p less than 0.05) to values exceeding those measured just before transplantation (2.1 +/- 1.0 vs 1.35 +/- 0.54 mg/dl) with low creatinine clearance (61 +/- 28 ml/min X 1.73 m2), and a 15% increase in plasma volume (+445 +/- 686 ml, p less than 0.02). Urinary excretion of vanilmandelic acid and total metanephrines was normal. Supine plasma renin activity was also normal (0.78 +/- 0.32 nmol/ml/hour). The stimulation of renin release after acute inhibition of converting enzyme by captopril was less marked than is usual in hypertensive subjects (0.86 +/- 0.54 nmol/liter/hour). Captopril induced a smaller drop in BP than nifedipine (-8 +/- 13/-6 +/- 10 mm Hg vs -14 +/- 11/-15 +/- 10 mm Hg). Levels of plasma aldosterone, angiotensinogen and converting enzyme activity were all normal, 308 +/- 147 pmol/liter, 712 +/- 164 nmol/ml and 30 +/- 6 mU/ml, respectively. It is concluded that hypertension is common in cardiac transplantation patients treated with cyclosporine, since 13 of our 15 subjects were normotensive before transplant.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3000160     DOI: 10.1016/0002-9149(85)90406-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  18 in total

1.  Potentiation of vascular smooth muscle cell activity by cyclosporin A.

Authors:  R Locher; R Huss; W Vetter
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Acute effects of cyclosporin and cremophor EL on endothelial function and vascular smooth muscle in the isolated rat heart.

Authors:  P Mankad; J Spatenka; Z Slavik; G O'Neil; A Chester; M Yacoub
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

Review 3.  Exercise following heart transplantation.

Authors:  R W Braith; D G Edwards
Journal:  Sports Med       Date:  2000-09       Impact factor: 11.136

4.  Changes in the venous compliance by bradykinin and angiotensin II and its significance for the vascular effects of cyclosporine-A.

Authors:  E Müller-Schweinitzer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-12       Impact factor: 3.000

Review 5.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

Review 6.  Central modulation of cyclosporine-induced hypertension.

Authors:  Hanan M El-Gowelli; Mahmoud M El-Mas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-11-29       Impact factor: 3.000

7.  Vascular mechanisms of cyclosporin-induced hypertension in the rat.

Authors:  J B Roullet; H Xue; D A McCarron; S Holcomb; W M Bennett
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

8.  A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome.

Authors:  Hao Guo; Changrim Lee; Mihir Shah; Srikanth R Janga; Maria C Edman; Wannita Klinngam; Sarah F Hamm-Alvarez; J Andrew MacKay
Journal:  J Control Release       Date:  2018-10-23       Impact factor: 9.776

Review 9.  Exercise and heart transplantation. A review.

Authors:  G Niset; L Hermans; P Depelchin
Journal:  Sports Med       Date:  1991-12       Impact factor: 11.136

10.  Acute haemodynamic effects of isradipine in hypertensive heart transplant recipients.

Authors:  H Aass; S Simonsen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.